Unprecedented, constructive disruption to drive the Microfluidic Devices Market
The Microfluidic Devices Market is slated to witness exponentiation going forward. The IoMT (Internet-of-Medical-Things) is already transforming every walk of life, including healthcare. Healthcare IT has let both – patients and doctors carry/download information about each other anywhere and anytime through their smartphones/tabs. In other words, more connectivity translates to better access to data, thereby rendering better healthcare for patients. This would be the future of the healthcare vertical in the upcoming period.
The global microfluidic devices market was
valued at US$ 5.1 Bn in 2020, and is estimated to surge at
a CAGR of 24% during the forecast period of 2021-2031. The
market in the European region is expected to expand at a reasonable CAGR
of around 14%, with global demand expected to reach US$ 21.5 Bn by
the end of 2031.
Globally, the microfluidic devices
market is witnessing significant growth due to increasing R&D investment in
pharmaceuticals, life science and rising point of care testing demand. New
trends in healthcare, such as health care at home, supports point of care
testing (POCT) as the most efficient and effective delivery of healthcare.
Get Going With Sample Of
Microfluidic Devices Market Report! https://www.persistencemarketresearch.com/samples/2995
Some of the major players in the
microfluidic device market:
- Roche Diagnostics.
- Abbott Laboratories.
- Siemens Healthcare.
- Agilent Technologies.
- Bio-Rad Laboratories, Inc.
- Fluidigm Corporation.
- Johnson & Johnson.
Miniaturization also reduces the
cost for screening compounds in pharmaceutical companies for cell biology
problems. In addition, microfluidic proteomic devices are increasingly being
used to quantify and identify proteins and to study interactions of different
proteins with reagent in array. Different materials such as glass, silicon,
polymer metal and ceramics, are used to manufacture microfluidic devices.
Get a Customized Scope to Match Your
Need Ask an Expert- sales@persistencemarketresearch.com
In North America, rising aging
population, increasing health awareness, rising chronic and lifestyle diseases,
technological developments for various home use applications, and proper
insurance coverage are driving the use of microfluidic devices in the market.
Usage of microfluidic technology in North America is high compared to other
regions of the world due to its early adoption and multiple applications in
different industries.
In Europe, the microfluidic devices
market is driven by rising diagnostic requirements due to increasing lifestyle
associated diseases, aging population and improving healthcare infrastructure.
On the other hand, increasing healthcare costs has shifted the focus of
healthcare from hospitals to home, which would increase the use of microfluidic
devices in the region.
However, Asia is becoming one of the
most attractive markets for medical device companies. The growth for
microfluidic devices is much faster than developed countries due to widening
health insurance penetration and up-gradation of health care systems. Asia is
one of the producers of generic drugs, which require microfluidic devices for
toxicity testing of drugs.
Roche Diagnostics, Abbott
Laboratories, Siemens Healthcare, Agilent Technologies, Bio-Rad Laboratories,
Inc, Fluidigm Corporation and Johnson & Johnson are some of the major
players of microfluidic devices market.
Keeping A Tab On Key Players In The
Microfluidic Devices Market? Go To “Purchase Now” To Decipher The Competitive
Analysis In Our Microfluidic Devices Market Report! https://www.persistencemarketresearch.com/checkout/2995
About Us: – Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Comments
Post a Comment